These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 34656559)

  • 1. Cisplatin resistance of NSCLC cells involves upregulation of visfatin through activation of its transcription and stabilization of mRNA.
    Lu Z; Fang Z; Guo Y; Liu X; Chen S
    Chem Biol Interact; 2022 Jan; 351():109705. PubMed ID: 34656559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visfatin is involved in the cisplatin resistance of osteosarcoma cells via upregulation of Snail and Zeb1.
    Wang D; Qian G; Wang J; Wang T; Zhang L; Yang P; Lin F
    Cancer Biol Ther; 2019; 20(7):999-1006. PubMed ID: 30975015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visfatin mediates doxorubicin resistance in human non-small-cell lung cancer via Akt-mediated up-regulation of ABCC1.
    Cao Z; Liang N; Yang H; Li S
    Cell Prolif; 2017 Oct; 50(5):. PubMed ID: 28762597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Periostin Contributes to Cisplatin Resistance in Human Non-Small Cell Lung Cancer A549 Cells via Activation of Stat3 and Akt and Upregulation of Survivin.
    Hu W; Jin P; Liu W
    Cell Physiol Biochem; 2016; 38(3):1199-208. PubMed ID: 26982182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Visfatin mediates doxorubicin resistance in human colorectal cancer cells via up regulation of multidrug resistance 1 (MDR1).
    Yan X; Zhao J; Zhang R
    Cancer Chemother Pharmacol; 2017 Aug; 80(2):395-403. PubMed ID: 28667355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation exposure triggers the malignancy of non‑small cell lung cancer cells through the activation of visfatin/Snail signaling.
    Xiao L; Mao Y; Tong Z; Zhao Y; Hong H; Wang F
    Oncol Rep; 2021 Mar; 45(3):1153-1161. PubMed ID: 33432364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visfatin Triggers the Cell Motility of Non-Small Cell Lung Cancer via Up-Regulation of Matrix Metalloproteinases.
    Wang G; Tian W; Liu Y; Ju Y; Shen Y; Zhao S; Zhang B; Li Y
    Basic Clin Pharmacol Toxicol; 2016 Dec; 119(6):548-554. PubMed ID: 27224551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ATF2 contributes to cisplatin resistance in non-small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/ATF2 pathway.
    Lo Iacono M; Monica V; Vavalà T; Gisabella M; Saviozzi S; Bracco E; Novello S; Papotti M; Scagliotti GV
    Int J Cancer; 2015 Jun; 136(11):2598-609. PubMed ID: 25359574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olean-28,13b-olide 2 plays a role in cisplatin-mediated apoptosis and reverses cisplatin resistance in human lung cancer through multiple signaling pathways.
    Zhu B; Ren C; Du K; Zhu H; Ai Y; Kang F; Luo Y; Liu W; Wang L; Xu Y; Jiang X; Zhang Y
    Biochem Pharmacol; 2019 Dec; 170():113642. PubMed ID: 31541631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Visfatin through STAT3 activation enhances IL-6 expression that promotes endothelial angiogenesis.
    Kim JY; Bae YH; Bae MK; Kim SR; Park HJ; Wee HJ; Bae SK
    Biochim Biophys Acta; 2009 Nov; 1793(11):1759-67. PubMed ID: 19751774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JARID2 promotes stemness and cisplatin resistance in non-small cell lung cancer via upregulation of Notch1.
    Wang Q; Wu J; Wei H; Huang H; Huang Y; Fang H; Gong X; Sun J; Wu Y; Lei C; Yu J; Hu D
    Int J Biochem Cell Biol; 2021 Sep; 138():106040. PubMed ID: 34246759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells.
    Yin Z; Zhang Y; Li Y; Lv T; Liu J; Wang X
    Acta Histochem; 2012 Feb; 114(2):151-8. PubMed ID: 21549414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
    Gao J; Meng Q; Zhao Y; Chen X; Cai L
    BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melatonin inhibits visfatin-induced inducible nitric oxide synthase expression and nitric oxide production in macrophages.
    Kang YS; Kang YG; Park HJ; Wee HJ; Jang HO; Bae MK; Bae SK
    J Pineal Res; 2013 Oct; 55(3):294-303. PubMed ID: 23869429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC).
    Codony-Servat C; Codony-Servat J; Karachaliou N; Molina MA; Chaib I; Ramirez JL; de Los Llanos Gil M; Solca F; Bivona TG; Rosell R
    Oncotarget; 2017 Jul; 8(29):47305-47316. PubMed ID: 28521301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells.
    Quan YH; Lim JY; Choi BH; Choi Y; Choi YH; Park JH; Kim HK
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):399-410. PubMed ID: 30515553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extracellular Visfatin-Promoted Malignant Behavior in Breast Cancer Is Mediated Through c-Abl and STAT3 Activation.
    Hung AC; Lo S; Hou MF; Lee YC; Tsai CH; Chen YY; Liu W; Su YH; Lo YH; Wang CH; Wu SC; Hsieh YC; Hu SC; Tai MH; Wang YM; Yuan SS
    Clin Cancer Res; 2016 Sep; 22(17):4478-90. PubMed ID: 27036136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer.
    Dalwadi H; Krysan K; Heuze-Vourc'h N; Dohadwala M; Elashoff D; Sharma S; Cacalano N; Lichtenstein A; Dubinett S
    Clin Cancer Res; 2005 Nov; 11(21):7674-82. PubMed ID: 16278387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p.
    Dong Y; Xu T; Zhong S; Wang B; Zhang H; Wang X; Wang P; Li G; Yang S
    Life Sci; 2019 Dec; 239():116984. PubMed ID: 31647948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous exposure of non-small cell lung cancer cells with wild-type EGFR to an inhibitor of EGFR tyrosine kinase induces chemoresistance by activating STAT3.
    Tang J; Guo F; Du Y; Liu X; Qin Q; Liu X; Yin T; Jiang L; Wang Y
    Int J Oncol; 2015 May; 46(5):2083-95. PubMed ID: 25695284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.